A consensus-based practical and daily guide for the treatment of acne patients

Journal of the European Academy of Dermatology and Venereology

Volumn 30, Issue 9, 2016, Pages 1480-1490

  Gollnick, H P ^a   Bettoli, V ^b   Lambert, J ^c   Araviiskaia, E ^d   Binic, I ^e   Dessinioti, C ^f   Galadari, I ^g   Ganceviciene, R ^h   Ilter, N ⁱ   Kaegi, M ^j   Kemeny, L ^k   Lopez Estebaranz J L ^l   Massa, A ^m   Oprica, C ^n,o   Sinclair, W ^p   Szepietowski, J C ^q   Dreno B ^r  

^a OTTO VON GUERICKE UNIVERSITY   (Germany)

^b UNIVERSITY HOSPITAL OF FERRARA   (Italy)

^c ANTWERP UNIVERSITY HOSPITAL   (Belgium)

^d PAVLOV FIRST SAINT PETERSBURG STATE MEDICAL UNIVERSITY   (Russian Federation)

^e UNIVERSITY OF NI   (Serbia)

^f UNIVERSITY OF ATHENS   (Greece)

^g UNITED ARAB EMIRATES UNIVERSITY   (United Arab Emirates)

^h VILNIUS UNIVERSITY   (Lithuania)

ⁱ GAZI UNIVERSITY FACULTY OF MEDICINE   (Turkey)

^j Hautzentrum Zürich   (Switzerland)

^k UNIVERSITY OF SZEGED   (Hungary)

^l HOSPITAL UNIVERSITARIO FUNDACIÓN ALCORCÓN   (Spain)

^m Clínica Dermatológica Dr António Massa ^*  (Portugal)

ⁿ KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^o Diagnostiskt Centrum Hud   (Sweden)

^p UNIVERSITY OF THE FREE STATE   (South Africa)

^q WROCLAW MEDICAL UNIVERSITY   (Poland)

^r UNIVERSITÉ DE NANTES   (France)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBIOTIC AGENT; AZELAIC ACID; ISOTRETINOIN; RETINOID; SALICYLIC ACID;

ACNE; ANTIBIOTIC THERAPY; ARTICLE; CONSENSUS; DISEASE SEVERITY; EVIDENCE BASED PRACTICE; HUMAN; MEDICATION COMPLIANCE; PHOTOSENSITIVITY; PRACTICE GUIDELINE; PREDOMINANT COMEDONAL ACNE; PREDOMINANT PAPULOPUSTULAR ACNE; PRIORITY JOURNAL; SKIN IRRITATION; TREATMENT FAILURE; TREATMENT RESPONSE; XEROSIS;

EID: 84983087363     PISSN: 09269959     EISSN: 14683083     Source Type: Journal    
DOI: 10.1111/jdv.13675     Document Type: Article

References (105)

1. Williams HC, Dellavalle RP, Garner S. Acne vulgaris. Lancet 2012; 379: 361–372.
2. Tan JK, Bhate K. A global perspective on the epidemiology of acne. Br J Dermatol 2015; 172(Suppl. 1): 3–12.
3. Fried RG, Webster GF, Eichenfield LF, Friedlander SF, Fowler JF Jr, Levy ML. Medical and psychosocial impact of acne. Semin Cutan Med Surg 2010; 29: 9–12.
4. Thiboutot D, Gollnick H, Bettoli V et al. New insights into the management of acne: an update from the Global Alliance to Improve Outcomes in Acne group. J Am Acad Dermatol 2009; 60: S1–S50.
5. Gollnick HP. From new findings in acne pathogenesis to new approaches in treatment. J Eur Acad Dermatol Venereol 2015; 29(Suppl. 5): 1–7.
6. Gollnick H, Cunliffe W, Berson D et al. Management of acne: a report from a Global Alliance to improve outcomes in acne. J Am Acad Dermatol 2003; 49: S1–S37.
7. Nast A, Dreno B, Bettoli V et al. European evidence-based (S3) guidelines for the treatment of acne. J Eur Acad Dermatol Venereol 2012; 26(Suppl. 1): 1–29.
8. Kubba R, Bajaj AK, Thappa DM et al. Acne in India: guidelines for management - IAA consensus document. Indian J Dermatol Venereol Leprol 2009; 75(Suppl. 1): 1–62.
9. Strauss JS, Krowchuk DP, Leyden JJ et al. Guidelines of care for acne vulgaris management. J Am Acad Dermatol 2007; 56: 651–663.
10. Abad-Casintahan F, Chow SK, Goh CL et al. Toward evidence-based practice in acne: consensus of an Asian Working Group. J Dermatol 2011; 38: 1041–1048.
11. Hayashi N, Akamatsu H, Iwatsuki K et al. Guidelines for treatment of acne vulgaris. Jpn J Dermatol 2008; 118: 1893–1923.
12. Dreno B, Poli F, Pawin H et al. Development and evaluation of a Global Acne Severity Scale (GEA Scale) suitable for France and Europe. J Eur Acad Dermatol Venereol 2011; 25: 43–48.
13. Del Rosso JQ. The role of skin care as an integral component in the management of acne vulgaris: part 1: the importance of cleanser and moisturizer ingredients, design, and product selection. J Clin Aesthet Dermatol 2013; 6: 19–27.
14. Thiboutot D, Pariser DM, Egan N et al. Adapalene gel 0.3% for the treatment of acne vulgaris: a multicenter, randomized, double-blind, controlled, phase III trial. J Am Acad Dermatol 2006; 54: 242–250.
15. Berger R, Barba A, Fleischer A et al. A double-blinded, randomized, vehicle-controlled, multicenter, parallel-group study to assess the safety and efficacy of tretinoin gel microsphere 0.04% in the treatment of acne vulgaris in adults. Cutis 2007; 80: 152–157.
16. Iraji F, Sadeghinia A, Shahmoradi Z, Siadat AH, Jooya A. Efficacy of topical azelaic acid gel in the treatment of mild-moderate acne vulgaris. Indian J Dermatol Venereol Leprol 2007; 73: 94–96.
17. Gamble R, Dunn J, Dawson A et al. Topical antimicrobial treatment of acne vulgaris: an evidence-based review. Am J Clin Dermatol 2012; 13: 141–152.
18. Thielitz A, Sidou F, Gollnick H. Control of microcomedone formation throughout a maintenance treatment with adapalene gel, 0.1%. J Eur Acad Dermatol Venereol 2007; 21: 747–753.
19. Hsu P, Litman GI, Brodell RT. Overview of the treatment of acne vulgaris with topical retinoids. Postgrad Med 2011; 123: 153–161.
20. Schmidt N, Gans EH. Tretinoin: a review of its anti-inflammatory properties in the treatment of acne. J Clin Aesthet Dermatol 2011; 4: 22–29.
21. Thielitz A, Lux A, Wiede A, Kropf S, Papakonstantinou E, Gollnick H. A randomized investigator-blind parallel-group study to assess efficacy and safety of azelaic acid 15% gel vs. adapalene 0.1% gel in the treatment and maintenance treatment of female adult acne. J Eur Acad Dermatol Venereol 2015; 29: 789–796.
22. Thielitz A, Gollnick H. Topical retinoids in acne vulgaris: update on efficacy and safety. Am J Clin Dermatol 2008; 9: 369–381.
23. Galvin SA, Gilbert R, Baker M, Guibal F, Tuley MR. Comparative tolerance of adapalene 0.1% gel and six different tretinoin formulations. Br J Dermatol 1998; 139(Suppl. 52): 34–40.
24. Thiboutot DM, Shalita AR, Yamauchi PS et al. Adapalene gel, 0.1%, as maintenance therapy for acne vulgaris: a randomized, controlled, investigator-blind follow-up of a recent combination study. Arch Dermatol 2006; 142: 597–602.
25. Alirezai M, George SA, Coutts I et al. Daily treatment with adapalene gel 0.1% maintains initial improvement of acne vulgaris previously treated with oral lymecycline. Eur J Dermatol 2007; 17: 45–51.
26. Gould DJ, Ead R, Cunliffe WJ. Oral tetracycline and retinoic acid gel in acne. Practitioner 1978; 221: 268–271.
27. Thiboutot DM, Fleischer AB, Del Rosso JQ, Rich P. A multicenter study of topical azelaic acid 15% gel in combination with oral doxycycline as initial therapy and azelaic acid 15% gel as maintenance monotherapy. J Drugs Dermatol 2009; 8: 639–648.
28. Gollnick HP, Finlay AY, Shear N. Can we define acne as a chronic disease? If so, how and when? Am J Clin Dermatol 2008; 9: 279–284.
29. Thielitz A, Helmdach M, Roepke EM, Gollnick H. Lipid analysis of follicular casts from cyanoacrylate strips as a new method for studying therapeutic effects of antiacne agents. Br J Dermatol 2001; 145: 19–27.
30. Madan RK, Levitt J. A review of toxicity from topical salicylic acid preparations. J Am Acad Dermatol 2014; 70: 788–792.
31. Dreno B. Topical antibacterial therapy for acne vulgaris. Drugs 2004; 64: 2389–2397.
32. Dreno B, Thiboutot D, Gollnick H et al. Antibiotic stewardship in dermatology: limiting antibiotic use in acne. Eur J Dermatol 2014; 24: 330–334.
33. Leccia MT, Auffret N, Poli F, Claudel JP, Corvec S, Dreno B. Topical acne treatments in Europe and the issue of antimicrobial resistance. J Eur Acad Dermatol Venereol 2015; 29: 1485–1492.
34. Gollnick HP, Draelos Z, Glenn MJ et al. Adapalene-benzoyl peroxide, a unique fixed-dose combination topical gel for the treatment of acne vulgaris: a transatlantic, randomized, double-blind, controlled study in 1670 patients. Br J Dermatol 2009; 161: 1180–1189.
35. Feldman SR, Werner CP, Alio Saenz AB. The efficacy and tolerability of tazarotene foam, 0.1%, in the treatment of acne vulgaris in 2 multicenter, randomized, vehicle-controlled, double-blind studies. J Drugs Dermatol 2013; 12: 438–446.
36. Graupe K, Cunliffe WJ, Gollnick HP, Zaumseil RP. Efficacy and safety of topical azelaic acid (20 percent cream): an overview of results from European clinical trials and experimental reports. Cutis 1996; 57: 20–35.
37. Dreno B, Bettoli V, Ochsendorf F et al. Efficacy and safety of clindamycin phosphate 1.2%/tretinoin 0.025% formulation for the treatment of acne vulgaris: pooled analysis of data from three randomised, double-blind, parallel-group, phase III studies. Eur J Dermatol 2014; 24: 201–209.
38. Gold LS, Tan J, Cruz-Santana A et al. A North American study of adapalene-benzoyl peroxide combination gel in the treatment of acne. Cutis 2009; 84: 110–116.
39. Tan JK. Adapalene 0.1% and benzoyl peroxide 2.5%: a novel combination for treatment of acne vulgaris. Skin Therapy Lett 2009; 14: 4–5.
40. Fagundes DS, Fraser JM, Klauda HC. New therapy update–A unique combination formulation in the treatment of inflammatory acne. Cutis 2003; 72: 16–19.
41. Ellis CN, Leyden J, Katz HI et al. Therapeutic studies with a new combination benzoyl peroxide/clindamycin topical gel in acne vulgaris. Cutis 2001; 67: 13–20.
42. Eichenfield LF, Alio Saenz AB. Safety and efficacy of clindamycin phosphate 1.2%-benzoyl peroxide 3% fixed-dose combination gel for the treatment of acne vulgaris: a phase 3, multicenter, randomized, double-blind, active- and vehicle-controlled study. J Drugs Dermatol 2011; 10: 1382–1396.
43. Jackson JM, Fu JJ, Almekinder JL. A randomized, investigator-blinded trial to assess the antimicrobial efficacy of a benzoyl peroxide 5%/clindamycin phosphate 1% gel compared with a clindamycin phosphate 1.2%/tretinoin 0.025% gel in the topical treatment of acne vulgaris. J Drugs Dermatol 2010; 9: 131–136.
44. Dreno B, Lambert J, Bettoli V. Are retinoid/antibiotic fixed-dose combination acne treatments associated with antibiotic resistance? Eur J Dermatol 2016; 26: 90–91.
45. Yentzer BA, Ade RA, Fountain JM et al. Simplifying regimens promotes greater adherence and outcomes with topical acne medications: a randomized controlled trial. Cutis 2010; 86: 103–108.
46. Zaenglein AL, Shamban A, Webster G et al. A phase IV, open-label study evaluating the use of triple-combination therapy with minocycline HCl extended-release tablets, a topical antibiotic/retinoid preparation and benzoyl peroxide in patients with moderate to severe acne vulgaris. J Drugs Dermatol 2013; 12: 619–625.
47. Dreno B, Kaufmann R, Talarico S et al. Combination therapy with adapalene-benzoyl peroxide and oral lymecycline in the treatment of moderate to severe acne vulgaris: a multicentre, randomized, double-blind controlled study. Br J Dermatol 2011; 165: 383–390.
48. Del Rosso JQ, Kim G. Optimizing use of oral antibiotics in acne vulgaris. Dermatol Clin 2009; 27: 33–42.
49. Sardana K, Garg VK, Sehgal VN, Mahajan S, Bhushan P. Efficacy of fixed low-dose isotretinoin (20 mg, alternate days) with topical clindamycin gel in moderately severe acne vulgaris. J Eur Acad Dermatol Venereol 2009; 23: 556–560.
50. Dreno B, Moyse D, Alirezai M et al. Multicenter randomized comparative double-blind controlled clinical trial of the safety and efficacy of zinc gluconate versus minocycline hydrochloride in the treatment of inflammatory acne vulgaris. Dermatology 2001; 203: 135–140.
51. Gollnick H, Albring M, Brill K. The effectiveness of oral cyproterone acetate in combination with ethinylestradiol in acne tarda of the facial type. Ann Endocrinol (Paris) 1999; 60: 157–166.
52. Williams C, Layton AM. Persistent acne in women: implications for the patient and for therapy. Am J Clin Dermatol 2006; 7: 281–290.
53. Dreno B, Layton A, Zouboulis CC et al. Adult female acne: a new paradigm. J Eur Acad Dermatol Venereol 2013; 27: 1063–1070.
54. Lam C, Zaenglein AL. Contraceptive use in acne. Clin Dermatol 2014; 32: 502–515.
55. Bettoli V, Zauli S, Virgili A. Is hormonal treatment still an option in acne today? Br J Dermatol 2015; 172(Suppl. 1): 37–46.
56. Thorneycroft l, Gollnick H, Schellschmidt I. Superiority of a combined contraceptive containing drospirenone to a triphasic preparation containing norgestimate in acne treatment. Cutis 2004; 74: 123–130.
57. Peck GL, Olsen TG, Butkus D et al. Isotretinoin versus placebo in the treatment of cystic acne. A randomized double-blind study. J Am Acad Dermatol 1982; 6: 735–745.
58. Gold LS, Cruz A, Eichenfield L et al. Effective and safe combination therapy for severe acne vulgaris: a randomized, vehicle-controlled, double-blind study of adapalene 0.1%-benzoyl peroxide 2.5% fixed-dose combination gel with doxycycline hyclate 100 mg. Cutis 2010; 85: 94–104.
59. Penna P, Meckfessel MH, Preston N. Fixed-dose combination gel of adapalene and benzoyl peroxide plus doxycycline 100 mg versus oral Isotretinoin for the treatment of severe acne: efficacy and cost analysis. Am Health Drug Benefits 2014; 7: 37–45.
60. Zouboulis CC, Bettoli V. Management of severe acne. Br J Dermatol 2015; 172(Suppl. 1): 27–36.
61. Ganceviciene R, Zouboulis CC. Isotretinoin: state of the art treatment for acne vulgaris. J Dtsch Dermatol Ges 2010; 8(Suppl. 1): S47–S59.
62. Leyden JJ, Bruce S, Lee CS et al. A randomized, phase 2, dose-ranging study in the treatment of moderate to severe inflammatory facial acne vulgaris with doxycycline calcium. J Drugs Dermatol 2013; 12: 658–663.
63. Bettoli V, Borghi A, Zauli S et al. Maintenance therapy for acne vulgaris: efficacy of a 12-month treatment with adapalene-benzoyl peroxide after oral isotretinoin and a review of the literature. Dermatology 2013; 227: 97–102.
64. Katsambas AD, Dessinioti C. Hormonal therapy for acne: why not as first line therapy? facts and controversies. Clin Dermatol 2010; 28: 17–23.
65. Kurokawa I, Danby FW, Ju Q et al. New developments in our understanding of acne pathogenesis and treatment. Exp Dermatol 2009; 18: 821–832.
66. Gaitanis G, Magiatis P, Hantschke M, Bassukas ID, Velegraki A. The Malassezia genus in skin and systemic diseases. Clin Microbiol Rev 2012; 25: 106–141.
67. Durdu M, Ilkit M. First step in the differential diagnosis of folliculitis: cytology. Crit Rev Microbiol 2013; 39: 9–25.
68. Boni R, Nehrhoff B. Treatment of gram-negative folliculitis in patients with acne. Am J Clin Dermatol 2003; 4: 273–276.
69. Lolis MS, Bowe WP, Shalita AR. Acne and systemic disease. Med Clin North Am 2009; 93: 1161–1181.
70. Chen W, Obermayer-Pietsch B, Hong JB et al. Acne-associated syndromes: models for better understanding of acne pathogenesis. J Eur Acad Dermatol Venereol 2011; 25: 637–646.
71. Zouboulis CC, Desai N, Emtestam L et al. European S1 guideline for the treatment of hidradenitis suppurativa/acne inversa. J Eur Acad Dermatol Venereol 2015; 29: 619–644.
72. Del Rosso JQ. The role of the vehicle in combination acne therapy. Cutis 2005; 76: 15–18.
73. Draelos ZD, Callender V, Young C, Dhawan SS. The effect of vehicle formulation on acne medication tolerability. Cutis 2008; 82: 281–284.
74. Baldwin HE. Tricks for improving compliance with acne therapy. Dermatol Ther 2006; 19: 224–236.
75. Kircik L, Friedman A. Optimizing acne therapy with unique vehicles. J Drugs Dermatol 2010; 9: s53–s57.
76. Chiou WL. Low intrinsic drug activity and dominant vehicle (placebo) effect in the topical treatment of acne vulgaris. Int J Clin Pharmacol Ther 2012; 50: 434–437.
77. Kircik LH. Evaluating tretinoin formulations in the treatment of acne. J Drugs Dermatol 2014; 13: 466–470.
78. Krautheim A, Gollnick H. Transdermal penetration of topical drugs used in the treatment of acne. Clin Pharmacokinet 2003; 42: 1287–1304.
79. Ferguson J, Johnson BE. Retinoid associated phototoxicity and photosensitivity. Pharmacol Ther 1989; 40: 123–135.
80. Gannon M, Underhill M, Wellik KE. Clinical inquiries. Which oral antibiotics are best for acne? J Fam Pract 2011; 60: 290–292.
81. Leyden JJ, Del Rosso JQ. Oral antibiotic therapy for acne vulgaris: pharmacokinetic and pharmacodynamic perspectives. J Clin Aesthet Dermatol 2011; 4: 40–47.
82. Blasiak RC, Stamey CR, Burkhart CN, Lugo-Somolinos A, Morrell DS. High-dose isotretinoin treatment and the rate of retrial, relapse, and adverse effects in patients with acne vulgaris. JAMA Dermatol 2013; 149: 1392–1398.
83. Cyrulnik AA, Viola KV, Gewirtzman AJ, Cohen SR. High-dose isotretinoin in acne vulgaris: improved treatment outcomes and quality of life. Int J Dermatol 2012; 51: 1123–1130.
84. Colburn WA, Gibson DM, Wiens RE, Hanigan JJ. Food increases the bioavailability of isotretinoin. J Clin Pharmacol 1983; 23: 534–539.
85. Taylor PW, Keenan MH. Pharmaceutical quality of generic isotretinoin products, compared with Roaccutane. Curr Med Res Opin 2006; 22: 603–615.
86. Gollnick HP, Zouboulis CC. Not all acne is acne vulgaris. Dtsch Arztebl Int 2014; 111: 301–312.
87. Kaya TI, Tursen U, Kokturk A, Ikizoglu G. An effective extraction technique for the treatment of closed macrocomedones. Dermatol Surg 2003; 29: 741–744.
88. Dreno B, Thiboutot D, Gollnick H et al. Large-scale worldwide observational study of adherence with acne therapy. Int J Dermatol 2010; 49: 448–456.
89. Snyder S, Crandell I, Davis SA, Feldman SR. Medical adherence to acne therapy: a systematic review. Am J Clin Dermatol 2014; 15: 87–94.
90. Katsambas AD. Why and when the treatment of acne fails. What to do. Dermatology 1998; 196: 158–161.
91. Katsambas AD, Dessinioti C. The difficult acne patient. In: Zouboulis CC, Katsambas AD, Kligman AM, eds. Pathogenesis and Treatment of Acne and Rosacea. Springer, Berlin, Heidelberg, New York, 2014: 383–388.
92. Kellett N, West F, Finlay AY. Conjoint analysis: a novel, rigorous tool for determining patient preferences for topical antibiotic treatment for acne. A randomised controlled trial. Br J Dermatol 2006; 154: 524–532.
93. Tripathi SV, Gustafson CJ, Huang KE, Feldman SR. Side effects of common acne treatments. Expert Opin Drug Saf 2013; 12: 39–51.
94. Bershad S, Kranjac SG, Parente JE et al. Successful treatment of acne vulgaris using a new method: results of a randomized vehicle-controlled trial of short-contact therapy with 0.1% tazarotene gel. Arch Dermatol 2002; 138: 481–489.
95. Zaenglein AL. Topical retinoids in the treatment of acne vulgaris. Semin Cutan Med Surg 2008; 27: 177–182.
96. Del Rosso JQ, Jitpraphai W, Bhambri S, Momin S. Clindamycin phosphate 1.2%- tretinoin 0.025% gel: vehicle characteristics, stability, and tolerability. Cutis 2008; 81: 405–408.
97. Kircik LH. Microsphere technology: hype or help? J Clin Aesthet Dermatol 2011; 4: 27–31.
98. Leyden J, Wortzman M, Baldwin EK. Tolerability of clindamycin/tretinoin gel vs. tretinoin microsphere gel and adapalene gel. J Drugs Dermatol 2009; 8: 383–388.
99. Goreshi R, Samrao A, Ehst BD. A double-blind, randomized, bilateral comparison of skin irritancy following application of the combination acne products clindamycin/tretinoin and benzoyl peroxide/adapalene. J Drugs Dermatol 2012; 11: 1422–1426.
100. Sagransky M, Yentzer BA, Feldman SR. Benzoyl peroxide: a review of its current use in the treatment of acne vulgaris. Expert Opin Pharmacother 2009; 10: 2555–2562.
101. Lee HE, Chang IK, Lee Y, Kim CD, Seo YJ, Lee JH, Im M. Effect of antihistamine as an adjuvant treatment of isotretinoin in acne: a randomized, controlled comparative study. JEADV 2014; 28: 1654–1660.
102. Korting HC, Borelli C, Schollmann C. Acne vulgaris. Role of cosmetics. Hautarzt 2010; 61: 126–131.
103. Goodman G. Cleansing and moisturizing in acne patients. Am J Clin Dermatol 2009; 10(Suppl. 1): 1–6.
104. Ananthapadmanabhan KP, Moore DJ, Subramanyan K, Misra M, Meyer F. Cleansing without compromise: the impact of cleansers on the skin barrier and the technology of mild cleansing. Dermatol Ther 2004; 17(Suppl. 1): 16–25.
105. Layton AM, Cunliffe WJ. Phototoxic eruptions due to doxycycline–a dose-related phenomenon. Clin Exp Dermatol 1993; 18: 425–427.